Hepion pharmaceuticals, inc. announces reverse stock split

Edison, n.j., may 10, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. eastern time today, may 10, 2023. hepion common stock will begin trading on a split-adjusted basis when the market opens on may 11, 2023 under the existing trading symbol “hepa.”
HEPA Ratings Summary
HEPA Quant Ranking